Phoebe Kuo1, Julie A Sosa2,3,4, Barbara A Burtness5,6, Zain A Husain5,7, Saral Mehra1,5, Sanziana A Roman2, Wendell G Yarbrough1,5,8, Benjamin L Judson1,5. 1. Division of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, Connecticut. 2. Division of Endocrine Surgery, Department of Surgery, Duke University School of Medicine, Durham, North Carolina. 3. Duke Clinical Research Institute, Durham, North Carolina. 4. Duke Cancer Institute, Durham, North Carolina. 5. Yale Cancer Center, New Haven, Connecticut. 6. Department of Medicine, Yale School of Medicine, New Haven, Connecticut. 7. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut. 8. Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: The current study was performed to characterize trends and survival outcomes for chemotherapy in the definitive and adjuvant treatment of hypopharyngeal cancer in the United States. METHODS: A total of 16,248 adult patients diagnosed with primary hypopharyngeal cancer without distant metastases between 1998 and 2011 were identified in the National Cancer Data Base. The association between treatment modality and overall survival was analyzed using Kaplan-Meier survival curves and 5-year survival rates. A multivariate Cox regression analysis was performed on a subset of 3357 cases to determine the treatment modalities that predict improved survival when controlling for demographic and clinical factors. RESULTS: There was a significant increase in the use of chemotherapy with radiotherapy both as definitive treatment (P<.001) and as adjuvant chemoradiotherapy with surgery (P=.001). This was accompanied by a decrease in total laryngectomy/pharyngectomy rates (P<.001). Chemoradiotherapy was associated with improved 5-year survival compared with radiotherapy alone in the definitive setting (31.8% vs 25.2%; log rank P<.001). Similarly, in multivariateanalysis, definitive radiotherapy was found to be associated with compromised survival compared with definitive chemoradiotherapy (hazard ratio, 1.51; P<.001). CONCLUSIONS: Survival analysis revealed that overall 5-year survival rates were higher for chemoradiotherapy compared with radiotherapy alone in the definitive setting, but were comparable between surgery with chemoradiotherapy and surgery with radiotherapy. Cancer 2016;122:1853-60.
BACKGROUND: The current study was performed to characterize trends and survival outcomes for chemotherapy in the definitive and adjuvant treatment of hypopharyngeal cancer in the United States. METHODS: A total of 16,248 adult patients diagnosed with primary hypopharyngeal cancer without distant metastases between 1998 and 2011 were identified in the National Cancer Data Base. The association between treatment modality and overall survival was analyzed using Kaplan-Meier survival curves and 5-year survival rates. A multivariate Cox regression analysis was performed on a subset of 3357 cases to determine the treatment modalities that predict improved survival when controlling for demographic and clinical factors. RESULTS: There was a significant increase in the use of chemotherapy with radiotherapy both as definitive treatment (P<.001) and as adjuvant chemoradiotherapy with surgery (P=.001). This was accompanied by a decrease in total laryngectomy/pharyngectomy rates (P<.001). Chemoradiotherapy was associated with improved 5-year survival compared with radiotherapy alone in the definitive setting (31.8% vs 25.2%; log rank P<.001). Similarly, in multivariateanalysis, definitive radiotherapy was found to be associated with compromised survival compared with definitive chemoradiotherapy (hazard ratio, 1.51; P<.001). CONCLUSIONS: Survival analysis revealed that overall 5-year survival rates were higher for chemoradiotherapy compared with radiotherapy alone in the definitive setting, but were comparable between surgery with chemoradiotherapy and surgery with radiotherapy. Cancer 2016;122:1853-60.
Authors: Japke F Petersen; Adriana J Timmermans; Boukje A C van Dijk; Lucy I H Overbeek; Laura A Smit; Frans J M Hilgers; Martijn M Stuiver; Michiel W M van den Brekel Journal: Eur Arch Otorhinolaryngol Date: 2017-10-28 Impact factor: 2.503
Authors: Pavel Dulguerov; Martina A Broglie; Guido Henke; Marco Siano; Paul Martin Putora; Christian Simon; Daniel Zwahlen; Gerhard F Huber; Giorgio Ballerini; Lorenza Beffa; Roland Giger; Sacha Rothschild; Sandro V Negri; Olgun Elicin Journal: Front Oncol Date: 2019-10-24 Impact factor: 6.244